deferasirox dominates deferoxamine for iron control

Inpharma 1643 - 21 Jun 2008 Deferasirox dominates deferoxamine for iron control Deferasirox represents a "cost-effective use of resources" in the UK for iron control in patients with iron overload resulting from frequent blood transfusions, say researchers from that region. They built an economic model using data obtained from clinical trials to assess the cost effectiveness of oral deferasirox ≥ 20 mg/kg/day versus standard iron chelation therapy with an equivalent dose of SC deferoxamine (≥ 35 mg/kg/day) in paediatric and adult patients with chronic iron overload due to frequent blood transfusions. * A time horizon of 1 year was adopted, and costs were calculated from the perspective of the UK NHS. The drug dose and cost was patient-weight related, and in the reference case considering patients with a mean weight of 42kg, deferasirox would dominate deferoxamine, being both less costly and resulting in more QALYs gained (difference of 0.176 QALYs). Deferasirox would also dominate among patients weighing a mean of 52kg. For patients weighing means of 62kg and 72kg, deferasirox would cost £7775 per QALY gained and £16 720 per QALY gained, respectively, compared with deferoxamine. Sensitivity analysis incorporating joint uncertainty in administration cost and other variables estimated that deferasirox would have an 80% probability of being cost effective at a willingness-to-pay value of £20 000/ QALY gained. * Financial sponsorship from Novartis was received for this study. Karnon J, et al. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Current Medical Research and Opinion 24: 1609-1621, No. 6, 2008 801108076 1 Inpharma 21 Jun 2008 No. 1643 1173-8324/10/1643-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 13-Dec-2016

213 views

Category:

Documents

1 download

Report

Download

Embed Size (px):

TRANSCRIPT

Inpharma 1643 - 21 Jun 2008

Deferasirox dominatesdeferoxamine for iron control

Deferasirox represents a "cost-effective use ofresources" in the UK for iron control in patients with ironoverload resulting from frequent blood transfusions, sayresearchers from that region.

They built an economic model using data obtainedfrom clinical trials to assess the cost effectiveness of oraldeferasirox ≥ 20 mg/kg/day versus standard ironchelation therapy with an equivalent dose ofSC deferoxamine (≥ 35 mg/kg/day) in paediatric andadult patients with chronic iron overload due to frequentblood transfusions.* A time horizon of 1 year wasadopted, and costs were calculated from the perspectiveof the UK NHS.

The drug dose and cost was patient-weight related,and in the reference case considering patients with amean weight of 42kg, deferasirox would dominatedeferoxamine, being both less costly and resulting inmore QALYs gained (difference of 0.176 QALYs).Deferasirox would also dominate among patientsweighing a mean of 52kg. For patients weighing meansof 62kg and 72kg, deferasirox would cost £7775 perQALY gained and £16 720 per QALY gained,respectively, compared with deferoxamine.

Sensitivity analysis incorporating joint uncertainty inadministration cost and other variables estimated thatdeferasirox would have an 80% probability of beingcost effective at a willingness-to-pay value of £20 000/QALY gained.* Financial sponsorship from Novartis was received for this study.

Karnon J, et al. Cost-utility analysis of deferasirox compared to standard therapywith desferrioxamine for patients requiring iron chelation therapy in the UnitedKingdom. Current Medical Research and Opinion 24: 1609-1621, No. 6,2008 801108076

Global Dominates of China s Development

Transdermal deferoxamine prevents pressure-induced diabetic … · 2015-01-02 · Transdermal deferoxamine prevents pressure-induced diabetic ulcers Dominik Duschera,1, Evgenios Neofytoua,1,

Slavery Dominates Politics

Pausing kinetics dominates strand-displacement ... - Technion · Pausing kinetics dominates strand-displacement polymerization by reverse transcriptase Omri Malik1,2,†, Hadeel Khamis1,3,†,

PRODUCT MONOGRAPH STERILE DEFEROXAMINE MESYLATE … · Injection for aluminum and/or iron overload, rare cases of mucormycosis, some with a fatal outcome have been reported. Deferoxamine

Effects of oral iron chelator deferasirox on human malignant … · 2012-10-02 · We demonstrated that deferasirox, a new oral iron-chelating agent, induced early apopto-sis in human

Esport Dominates Growth-Dingittv

Digital Communication Dominates Customer Engagement

Section 15.3: Slavery Dominates Politics

Warriors offense dominates Spartans

Vakalarla Deferasirox Doz Yönetemi · Vakalarla Deferasirox Doz Yönetemi Doç. Dr. Şule Ünal Hacettepe Üniversitesi Çocuk Hematoloji

Perry dominates in South Carolina - FITSNews